# COMBI-AD (NCT01682083)

> Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01682083
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Melanoma
- Interventions: Dabrafenib; Trametinib; Placebos
- Enrollment: 870
- Primary outcome: Percentage of Participants With Relapse-free Survival (RFS) Events
- Primary outcome: Relapse-free Survival (RFS)

## Commentary we found

- Podcasts: 24
- YouTube: 12
- X threads: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=combi-ad-nct01682083

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01682083", "email": "<work email>"}; the inbox owner confirms by the emailed link.